Begoña Pla Peris

Begoña Pla Peris

Auto-generated profile, based on publicly available information

Begoña Pla Peris

Hospital General de Castellon, Castellón de la Plana, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2020 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
BPBegoña Pla
Begoña Pla
AAAlfonso Arranz
Alfonso Arranz
CKCarolina Knott
Carolina Knott
MSMiguel Antonio Sampedro-Núñez
Miguel Antonio Sampedro-Núñez
SJSara Jiménez
Sara Jiménez
MMMonica Marazuela
Monica Marazuela
Aim: To examine the impact of the lockdown caused by the COVID-19 pandemic on both the glycemic control and the daily habits of a group of patients with type 1 diabetes mellitus (T1DM) using flash continuous glucose monitoring devices (flash CGMs). Methods: Retrospective analysis based on all the information gathered in virtual consultations from a cohort of 50 adult patients with T1DM with follow-up at our site. We compared their CGM metrics during lockdown with their own previous data before the pandemic occurred, as well as the potential psychological and therapeutic changes. Results: We observed a reduction of average glucose values: 160.26 ± 22.55 mg/dL vs 150 ± 20.96 mg/dL, P = .0009; estimated glycosylated hemoglobin: 7.21 ± 0.78% vs 6.83 ± 0.71%, P = .0005; glucose management indicator 7.15 ± 0.57% vs 6.88 ± 0.49%; P = .0003, and glycemic variability: 40.74 ± 6.66 vs 36.43 ± 6.09 P < .0001. Time in range showed an improvement: 57.46 ± 11.85% vs a 65.76 ± 12.09%, P < .0001, without an increase in percentage of time in hypoglycemia. Conclusions: COVID-19 lockdown was associated with an improvement in glycemic control in patients with T1DM using CGMs.

11 January 2022 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
BPB. Pla Peris
B. Pla Peris
AAA. Á. Merchante Alfaro
A. Á. Merchante Alfaro
FRF. J. Maravall Royo
F. J. Maravall Royo
PGP. Abellán Galiana
P. Abellán Galiana
SNS. Pérez Naranjo
S. Pérez Naranjo
MBM. González Boillos
M. González Boillos

27 November 2023 in Endocrine
Verified
Journal Article
Open access
PDF file
PRPaola Parra Ramírez
Paola Parra Ramírez
PRPatricia Martín Rojas-Marcos
Patricia Martín Rojas-Marcos
MFMiguel PAJA FANO
Miguel PAJA FANO
MBMargarita González Boillos
Margarita González Boillos
BPBegoña Pla Peris
Begoña Pla Peris
Marta Araujo-CastroMarta Araujo-Castro
Marta Araujo-Castro
Purpose To evaluate whether the clinical, biochemical and radiological features of patients with primary aldosteronism (PA) can predict both main subtypes of PA. Methods A retrospective multicenter study of PA patients followed in 27 Spanish tertiary hospitals (SPAIN-ALDO Register). Only patients with confirmed unilateral or bilateral PA based on adrenal venous sampling (AVS) and/or postsurgical biochemical cure after adrenalectomy were included. Supervised regression techniques were used for model development. Results 328 patients [270 unilateral PA (UPA), 58 bilateral PA (BPA)] were included. The area under the curve (AUC) for aldosterone/potassium ratio and aldosterone responses following saline infusion test were 0.602 [95%CI 0.520 to 0.684] and 0.574 [95% CI 0.446–0.701], respectively, to differentiate UPA from BPA. The AUC was 0.825 [95% 0.764–0.886] when the prediction model with seven parameters – comorbidities (dyslipidemia, cerebrovascular disease, sleep apnea syndrome [SAS]), systolic blood pressure (SBP), plasma aldosterone levels (PAC), hypokalemia and unilateral adrenal nodule >1 cm and normal contralateral adrenal gland on CT/MRI – was used. In patients without comorbidities, hypokalemia, SBP > 160 mmHg, PAC > 40 ng/dL, and unilateral adrenal lesions were associated with a likelihood of having a UPA of 98.5%. The chance of BPA was higher in individuals with comorbidities, SBP < 140 mmHg, normokalemia, low PAC levels, and no adrenal tumors on the CT/MRI (91.5%). Conclusion A combination of high PAC, SBP > 160 mmHg, low serum potassium, a unilateral adrenal nodule>1 cm and no comorbidities could predict a UPA with a 98.5% accuracy.

1 September 2023 in JCEM Case Reports
Verified
Journal Article
Open access
PDF file
BPBegoña Pla Peris
Begoña Pla Peris
PAPablo Abellán-Galiana
Pablo Abellán-Galiana
FRFrancisco Javier Maravall Royo
Francisco Javier Maravall Royo
AAAgustín Ángel Merchante Alfaro
Agustín Ángel Merchante Alfaro
We present 2 cases referred for evaluation of Graves disease (GD) associated with an incidental mediastinal mass. Chest computed tomography (CT) scans showed a 1.2 × 2.4 × 4.3 cm and a 5.7 × 2.6 × 7 cm thymic enlargement, respectively, consistent with thymic hyperplasia (TH) in the 2 patients. Patient 1 had been assessed by thoracic surgery for the mediastinal mass, and thymectomy had been performed to exclude thymoma, with an anatomopathological diagnosis consistent with thymic hyperplasia. Patient 2 was treated with methimazole. CT scan was repeated after he maintained a euthyroid state, which revealed total regression of the mass. There is a well-documented association between these 2 entities, but it is often underdiagnosed and unrecognized in routine clinal practice. The benign evolution, as evidenced by regression of thymic hyperplasia after resolution of the hyperthyroidism, is characteristic. These cases highlight the importance of recognizing the association of GD and TH and warrant a conservative approach, preventing unnecessary thymic evaluation and surgery.

1 October 2025 in Diabetes Technology & Therapeutics
Verified
Journal Article
Open access
HAHospital Central de Asturias
Hospital Central de Asturias
EÁElías Delgado Álvarez
Elías Delgado Álvarez
CLCarmen Lambert
Carmen Lambert
MRManuela Moreira Rodríguez
Manuela Moreira Rodríguez
LULidia Urbon
Lidia Urbon
ETEdelmiro Luis Menéndez Torre
Edelmiro Luis Menéndez Torre
Introduction: Achieving optimal glycemic control in patients with type 1 diabetes mellitus (PwT1DM) is essential to prevent complications. Continuous subcutaneous insulin infusion (CSII) systems combined with continuous glucose monitoring (CGM) have improved outcomes, but the effectiveness of additional technologies, such as mobile apps and hybrid closed-loop systems (HCLSs), remains unclear. This study evaluates glycemic control and quality of life (QoL) in adult PwT1DM transitioning from multiple daily injections (MDI) to a CSII, first with the Mylife™ Dose app and subsequently switching to an HCLS. Materials and Methods: This was a 10-month, multicenter, open-label sequential study involving 135 adults with type 1 diabetes (T1D), all of whom were using isCGM and MDI before transitioning to CSII, first with the Mylife Dose app and later to an HCLS. Glycemic control (glycated hemoglobin [HbA1c], time in range [TIR], time below range, time above range), insulin requirements, and QoL/treatment satisfaction/hypoglycemia perception (Diabetes Quality of Life questionnaire, Diabetes Treatment Satisfaction Questionnaire, Clarke’s test) were measured at each of the four study visits. Results: Transitioning from MDI to CSII showed modest improvements in HbA1c (7.57%–7.42%; P = 0.02) and TIR (56.3%–60.4%; P < 0.01). The introduction of the Mylife Dose app did not provide significant additional improvements in glycemic control or QoL, although it provided an additional tool for diabetes management. However, switching to an HCLS resulted in substantial improvements in HbA1c (6.7%), TIR (73.1%), and QoL, with over 70% of patients achieving an HbA1c <7%. Insulin requirements increased slightly with the HCLS, primarily due to basal insulin. Adherence was high, with 88.1% completing the study. Conclusions: The Mylife Dose app does not improve glycemic control or QoL significantly but offers convenience for patients with T1D. In contrast, HCLSs provide significant metabolic and QoL benefits, supporting their integration into T1D management with appropriate reimbursement policies.